Endocrine Abstracts

Introduction: In addition to the medication prescribed by their doctors, patients may recourse to natural medicine and take herbal medications without thinking about their potential side effects and interactions with other drugs.Case Report: A 39-year-old female, with personal history of iron deficiency anemia, regular menses but long-standing dysmenorrhea and polymenorrhea and reactive anxiety-depressive disorder, complained of frequent intermenstrual s...

Sleep disordered breathing (SDB), including obstructive sleep apnoea (OSA), is associated with excessive daytime somnolence, and impacts significantly on quality of life in affected individuals. It also predisposes to premature cardiovascular (hypertension, congestive cardiac failure, myocardial infarction, sudden death, and stroke) and metabolic (diabetes mellitus and dyslipidaemia) dysfunction.SDB is a well-recognised complication of acromegaly. In mos...

It is generally accepted that hepatic responses to α-adrenergic agonists are dependent on the redistribution of intracellular and also extracellular Ca2+. Besides, phenylephrine induces significant K+ flux changes and plasma membrane hyperpolarisation. Earlier it was shown that K+ channel blockers as well as chelating of extracellular Ca2+ with EGTA could inhibit phenylephrine-induced metabolic responses and activation of mitoch...

Introduction/Aim: New oral anticoagulant drugs such as the factor Xa inhibitor rivaroxaban are often preferred to the classic coumarins because they do not need frequent blood-test monitoring and have fever interactions with other drugs and foodstuffs. They are not, however, interaction free. Rivaroxaban is metabolized by oxidative degradation catalyzed by CYP3A4/5 and CYP2J2; it is also a substrate of the P-gp and ABCG2 efflux transporter proteins. CYP3A4 activity enhancers s...

The GIRFT (Getting It Right First Time) visits, about which we have consulted the membership of the Society for Endocrinology and had positive feedback from many members, have now started. We have done four pilots in Birmingham, Leicester, Oxford and York. The objectives are to try to introduce a quantitative approach to help demonstrate best practice. It will explore surgical outcome data and complication rates with regard to thyroid, parathyroid, adrenal, pituitary and neuro...

Objective: Objective to study the hypolipidemic efficacy, hepatoprotective activity, and tolerance of the fixed-dose combination of essential phospholipids with methionine (EPL+M) - Eslidine in the combination therapy with A in patients (pts) with cardiovascular diseases (CVD) and type 2 DM who suffer from hyperlipidemia (HL) in order to optimize their treatment in daily clinical practice.Subjects and methods: The trial enrolled 60 pts (mean age 58.1&#17...

Introduction: Therapeutic approach of patients (pts) with metastatic renal cell carcinoma (mRCC) may include the use of biological agents such as m-TOR inhibitors: temsirolimus (TM) and everolimus (EV). Its use is associated with metabolic dysfunction, especially with everolimus: hyperglycemia (37% TM treated pts vs 72% EV treated pts), hypercholesterolemia (25% TM treated pts vs 81% EV treated pts) and hypertriglyceridemia (30% TM treated pts vs 73% EV treated pts). Discontin...

Introduction: The thyroid is a multifunctional endocrine gland which, by its hormones, affects all the organs, metabolisms and nonspecific defence of the body. The aim of this study is to establish if endogenous thyroxin (FT4) is involved in the nonspecific defence of the organism.Material and methods: 94 patients were included in the study, 47 with hyperthyroidism and 47 with hypothyroidism, 81 women, 13 men aged 7–78. FT4 was...

Type 1 diabetes is a chronic autoimmune disease with a subclinical prodromal period characterized by the presence of circulating antibodies to various islet cell proteins. Our main objective is to estimate the prevalence of diabetes-associated autoantibodies in a group of 1st degree relatives, compared to healthy control subjects. Also, we tried to assess the insulin secretory capacity in subjects having multiple antibodies using first phase insulin response (FPIR) to intraven...

M shows an antiproliferative effect. In vivo, M reduces TSH in type 2 diabetes mellitus (T2DM) and DTC aggressiveness in DTC with T2DM. The aim of the study was to evaluate in DTC diabetic (Gr1, n=30 under M 1500 mg/day) and non-diabetic without (Gr2, n=83) or under M (gr3, n=84; M 1000 mg/day) the adjuvant role of M. Clinical and laboratory examinations were performed up to 24 months. At baseline the DTC groups were similar for age, gender, tumor st...